Placeholder Banner

BIO Applauds Release of New National Biodefense Strategy

September 19, 2018

BIO Applauds Release of New
National Biodefense Strategy

Washington, DC (September 19, 2018): Yesterday, the Trump Administration announced the release of a new National Biodefense Strategy to better defend and protect the United States against biological threats. Tom DiLenge, BIO's President of Advocacy, Law & Public Policy, issued the following statement in response:

“I applaud the Administration for recognizing the importance of strengthening our national biodefense and preparedness efforts. Our nation continues to face a wide range of biological threats, and this strategy is an important step in the right direction. BIO’s member companies are at the forefront of the research, development and manufacturing of medical countermeasures, and we are committed to working with policymakers to ensure these life-saving products are available should the need arise. This week marks the 17th anniversary of the anthrax attacks that occurred within the United States, reminding us of the need to remain vigilant and ready to respond to the many unpredictable threats facing society.”


Jim Greenwood, BIO’s President and CEO, is a member of the bipartisan Blue Ribbon Study Panel on Biodefense, which was established in 2014 to provide a comprehensive assessment of the state of U.S. biodefense efforts, and to issue recommendations that will foster change. The development and release of the Administration's recent National Biodefense Strategy was among the top recommendations of the Panel's 2015 report: A National Blueprint for Biodefense.


Discover More
The Biden administration just announced its intent for the United States to join the COVAX vaccine facility, which aims to deliver COVID-19 vaccines to poor and under-developed countries. Dr. Michelle McMurry-Heath, president and CEO of the…
Washington, D.C. (January 20, 2021) — The BiotechnologyInnovation Organization (BIO) and the Low Carbon Fuels Coalition (LCFC) today released the following statement in support of New Mexico Governor Michelle Lujan Grisham’s inclusion of a…
In his last day in office, former President Donald Trump proposed a sweeping change to Medicare’s “Part D” drug benefit. Billed as a demonstration project through the Centers for Medicare and Medicaid Innovation (CMMI), this new policy would allow…